Molecular Insights Pharmaceuticals

Molecular Insights Pharmaceuticals is a biopharmaceutical company focused on the development of targeted radiopharmaceuticals for the imaging and treatment of cancer and cardiovascular diseases. The company pioneered the 'theranostic' approach, utilizing the same targeting vector for both diagnostic imaging and therapeutic intervention. Its lead product, Azedra (iobenguane I 131), was developed for the treatment of rare neuroendocrine tumors and eventually received FDA approval. The company's pipeline also featured innovative candidates targeting prostate-specific membrane antigen (PSMA) for prostate cancer. Molecular Insights was acquired by Progenics Pharmaceuticals in 2013, and its assets are now part of Lantheus.